Elvitegravir–Cobicistat–Emtricitabine–Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis. (28th June 2019)

• Record Type: Journal Article
• Authors: Gantner, Pierre; Hessamfar, Mojgan; Souala, Mohamed Faouzi; Valin, Nadia; Simon, Anne; Ajana, Faiza; Bouvet, Elisabeth; Rouveix, Elisabeth; Cotte, Laurent; Bani-Sadr, Firouzé; Hustache-Mathieu, Laurent; Lebrette, Marie-Gisèle; Truchetet, François; Galempoix, Jean-Marie; Piroth, Lionel; Pellissier, Gérard; Muret, Patrice; Rey, David
• Is Part Of: Clinical infectious diseases. Volume 70:Number 5(2020)
• Page Start: 943
• Page End: 946
• Publication Date: 2019-06-28
• Subjects: HIV -- postexposure prophylaxis -- completion -- adherence -- adverse events; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciz577
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: : We evaluated an elvitegravir–cobicistat–emtricitabine–tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen could be appropriate for postexposure prophylaxis. Clinical Trials Registration: NCT02998320.